Company Sanjivani Paranteral Limited

531569

INE860D01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:54 11/06/2026 pm IST			5-day change	1st Jan Change
140.15 ^INR	+0.11%		-2.47%	-39.47%

16/05	Sanjivani Paranteral Limited, Q4 2026 Earnings Call, May 15, 2026
14/05	Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI

Business description: Sanjivani Paranteral Limited

Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. The Companyâ€™s products include oral solids, small volume parenteral and sterile powder formula. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, multivitamin, nutrition, diuretic, anti-hypertensive, and others. Its anti-biotic includes Netilmicin Sulfate, Amikacin Sulfate, and Gentamycin Sulfate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic include Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamins include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, and Diazepam. Its diuretic includes Furosemide.

Number of employees: 40

Sales by Activity: Sanjivani Paranteral Limited

Fiscal Period: March	2021 (INR)	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)
Manufacturing Pharmaceutical Products	25Cr	31Cr	35Cr	54Cr	70Cr

See all business segments

Geographical breakdown of sales: Sanjivani Paranteral Limited

Fiscal Period: March	2021 (INR)	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)
Export	14Cr	19Cr	23Cr	40Cr	53Cr
India	9.02Cr	8.47Cr	17Cr	12Cr	11Cr
Unallocated	2.02Cr	2.92Cr	-4.02Cr	2.12Cr	6.54Cr

See all geographic segments

Executive Committee: Sanjivani Paranteral Limited

Manager	Title	Age	Since
Ashwini Anamisharan Khemka CEO	Chief Executive Officer	55	01/01/1997
Pritesh Jain DFI	Director of Finance/CFO	44	08/04/2024
Ravikumar V. Bogam CMP	Compliance Officer	38	16/08/2024

See SANJIVANI PARANTERAL LIMITED governance

Composition of the Board of Directors: Sanjivani Paranteral Limited

Director	Title	Age	Since
Ashwini Anamisharan Khemka CHM	Chairman	55	01/01/1997
Monika Amit Singhania BRD	Director/Board Member	52	24/03/2022
Srivardhan Ashwani Khemka BRD	Director/Board Member	-	24/03/2022
Abhay Milan Shah BRD	Director/Board Member	30	08/04/2024
Basant Shrivastava BRD	Director/Board Member	69	11/09/2025

Composition of the Board of Directors

Shareholders: Sanjivani Paranteral Limited

Name	Stocks	%	Valuation
Srivardhan Ashwani Khemka 29.51 %	36,25,651	29.51 %	6 M ₹

List of SANJIVANI PARANTERAL LIMITED shareholders

Company details: Sanjivani Paranteral Limited

Sanjivani Paranteral Ltd.

02 Business Park

400080, Mumbai

http://www.sanjivani.co.in

address Sanjivani Paranteral Limited(531569)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SANJIVANI PARANTERAL LIMITED	+0.11%	-2.47%	-41.59%	+110.15%	1.81Cr
ELI LILLY AND COMPANY	+2.08%	+3.31%	+43.77%	+161.06%	1,01300Cr
JOHNSON & JOHNSON	+0.49%	+5.20%	+54.60%	+50.12%	57TCr
ABBVIE INC.	+0.30%	+0.49%	+18.04%	+64.12%	40TCr
ROCHE HOLDING AG	-0.37%	+4.97%	+21.24%	+15.95%	32TCr
ASTRAZENECA PLC	+0.85%	+0.18%	+24.50%	+14.78%	28TCr
NOVARTIS AG	+2.10%	+4.92%	+25.30%	+33.80%	27TCr
AMGEN INC.	+3.69%	+1.38%	+20.06%	+61.19%	18TCr
NOVO NORDISK A/S	-0.19%	-0.46%	-45.32%	-48.35%	19TCr
GILEAD SCIENCES, INC.	+3.58%	-2.45%	+15.29%	+61.84%	15TCr
Average	+1.25%	+2.12%	+13.59%	+52.47%	33.89TCr
Weighted average by Cap.	+1.28%	+3.99%	+29.71%	+72.92%